Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Net Income towards Common Stockholders of $37.9 million for Q1 2026, up 211.47% on a QoQ basis from $12.2 million in Q4 2025, and up 1322.65% year-over-year from $2.7 million in Q1 2025.
Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at $37.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 1322.65% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.2 million (up 235.04% YoY) and the FY2025 annual result came in at $83.2 million, up 178.88% from the prior year.
- Net Income towards Common Stockholders was $37.9 million for Q1 2026 at Zevra Therapeutics, up from $12.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $74.7 million in Q2 2025 and bottomed at -$35.7 million in Q4 2024.
- A 5-year average of -$4.1 million and a median of -$9.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 674.39% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Net Income towards Common Stockholders stood at -$9.0 million in 2022, then tumbled by 120.51% to -$19.9 million in 2023, then plunged by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025, then soared by 211.47% to $37.9 million in 2026.
- Business Quant data shows ZVRA's Net Income towards Common Stockholders at $37.9 million in Q1 2026, $12.2 million in Q4 2025, and -$544000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -11.77 Mn |
| Dec 31, 2022 | -9.02 Mn |
| Sep 30, 2022 | -6.62 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | -10.70 Mn |